## Abstract A real‐time polymerase chain reaction assay for quantitation of Epstein‐Barr virus (EBV) DNA in serum was developed. This assay detected EBV DNA in 24 (89%) of 27 sera from patients with infectious mononucleosis, but only in 9 (18%) of 51 sera from EBV carriers (__P__ < 0.001) and in no
Semiquantitative PCR analysis of Epstein-Barr virus DNA in clinical samples of patients with EBV-associated diseases
✍ Scribed by Astrid Meerbach; Bernd Gruhn; Renate Egerer; Udo Reischl; Felix Zintl; Peter Wutzler
- Publisher
- John Wiley and Sons
- Year
- 2001
- Tongue
- English
- Weight
- 168 KB
- Volume
- 65
- Category
- Article
- ISSN
- 0146-6615
- DOI
- 10.1002/jmv.2040
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
The laboratory diagnosis of primary and reactivated Epstein‐Barr virus (EBV) infection is based on serologic methods in immunocompetent patients. However, in immunocompromised patients, serologic data are difficult to interpret and do not often correlate with clinical data. In order to find a useful and practical marker for diagnosis of EBV‐related diseases, a polymerase chain reaction (PCR) assay was established for semiquantitative detection of EBV sequences. The method was based on a nested PCR, using primers of the virus capsid antigen p23 region and an endpoint dilution. This method was carried out on 68 plasma samples, 68 samples of peripheral blood mononuclear cells and 5 cerebrospinal fluid samples of 39 patients with various diseases to evaluate the EBV‐genome copy number. Samples from patients suffering from infectious mononucleosis served as positive controls for active EBV infection. In 5 patients with infectious mononucleosis, high copy numbers of EBV genomes in peripheral blood mononuclear cells were detected within a range of 1,000–40,000 copies in 10^5^ peripheral blood mononuclear cells. In contrast, samples from 19 latently infected persons either showed low copy numbers (10–100 in 10^5^ peripheral blood mononuclear cells) or were EBV PCR negative. Comparable results were observed in seven renal transplant patients without any symptoms. The practical value of the semiquantitative detection of EBV DNA was demonstrated in three bone marrow transplant recipients. Two developed a lymphoproliferative disease associated with extremely high amounts of EBV DNA in plasma (16,000 and 50,000 copies/ml, respectively) and peripheral blood mononuclear cells (100,000 and 6.5 million copies in 10^5^ peripheral blood mononuclear cells, respectively). The high EBV load in plasma and peripheral blood mononuclear cells was reduced dramatically after successful antiviral therapy in one case. The third bone marrow transplant recipient developed an EBV‐induced transverse myelitis with an increased number of EBV‐genome copies in peripheral blood mononuclear cells and EBV‐positive cerebrospinal fluid samples. After combined antiviral and immune therapy, the EBV‐genome copy numbers decreased and the patient recovered completely. These data demonstrate a good correlation between semiquantitative detection of EBV genomes and clinical findings. The method is recommended for the diagnosis of EBV‐associated diseases in patients after transplantation, as well as for monitoring the response to therapy. J. Med. Virol. 65:348–357, 2001. © 2001 Wiley‐Liss, Inc.
📜 SIMILAR VOLUMES
DNA from malignant cells is present in the serum/plasma of cancer patients and DNA from this source is amenable to analysis by polymerase chain reaction (PCR). In the present study, we evaluated whether Epstein-Barr virus (EBV) DNA is present in the serum of patients with EBV-associated Hodgkin's di
gp350 of Epstein-Barr virus (EBV) induces a strong immune response in EBV-infected individuals, but relatively little is known about the clinical relevance of this response in patients with different EBV-associated malignancies and other diseases. Using our gp350-expressing cell clones, we studied g
## Abstract ## BACKGROUND Serologic measurement of antibodies to Epstein–Barr virus (EBV) immunoglobulin A/viral capsid antigen (IgA/VCA) and early antigen (IgA/EA) has been used widely to screen for nasopharyngeal carcinoma (NPC) in China. Recently, it was found that plasma EBV DNA concentration
## Abstract Biopsy specimens from Alaskan Native patients with nasopharyngeal carcinoma (NPC) and from other patients seen on the otolaryngology service were tested for Epstein‐Barr virus‐specific DNA and nuclear antigen (EBNA). Serum samples from both groups were tested for various EBV‐related ant